The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

Jochen Springer; Anika Tschirner; Kai Hartman; Stephan von Haehling; Stefan D Anker; Wolfram Doehner

doi:10.1016/j.ijcard.2013.05.063

The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

Jochen Springer, Anika Tschirner, Kai Hartman, Stephan von Haehling, Stefan D Anker, Wolfram Doehner

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.

Original language	English
Pages (from-to)	3527-3531
Number of pages	5
Journal	International Journal of Cardiology
Volume	168
Issue number	4
DOIs	https://doi.org/10.1016/j.ijcard.2013.05.063
Publication status	Published - 9 Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijcard.2013.05.063

Cite this

@article{bb8673987475438eb3db521ab42434b2,

title = "The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy",

abstract = "Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.",

author = "Jochen Springer and Anika Tschirner and Kai Hartman and {von Haehling}, Stephan and Anker, {Stefan D} and Wolfram Doehner",

year = "2013",

month = oct,

day = "9",

doi = "10.1016/j.ijcard.2013.05.063",

language = "English",

volume = "168",

pages = "3527--3531",

journal = "International Journal of Cardiology",

issn = "1874-1754",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

AU - Springer, Jochen

AU - Tschirner, Anika

AU - Hartman, Kai

AU - von Haehling, Stephan

AU - Anker, Stefan D

AU - Doehner, Wolfram

PY - 2013/10/9

Y1 - 2013/10/9

N2 - Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.

AB - Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.

U2 - 10.1016/j.ijcard.2013.05.063

DO - 10.1016/j.ijcard.2013.05.063

M3 - Article

C2 - 23751350

VL - 168

SP - 3527

EP - 3531

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 1874-1754

IS - 4

ER -